TacticScaleWhat Shenzhen New Industries Biomedical Engineering (新产业) Does & How It Makes Money (300832.SZ)
Updated October 2026 · reflects Shenzhen New Industries Biomedical Engineering's latest reported financials
Chinese maker of lab diagnostic analyzers and test reagents. The company sells clinical laboratory analyzers to hospitals and earns ongoing revenue by supplying the in vitro diagnostic reagents those instruments use for testing.
How Shenzhen New Industries Biomedical Engineering makes money
The company sells clinical laboratory analyzers to hospitals and earns ongoing revenue by supplying the in vitro diagnostic reagents those instruments use for testing.
What Shenzhen New Industries Biomedical Engineering does
Shenzhen New Industries Biomedical Engineering, founded in 1995 and based in Shenzhen, develops, makes and sells clinical laboratory instruments and in vitro diagnostic (IVD) reagents. Its main customers are hospitals in China and abroad. The product range covers immunoassay analyzers, biochemistry/electrolyte analyzers, integrated systems, lab automation, molecular diagnostics, hemolumi and rapid test solutions. The business combines instruments with consumables. Hospitals buy or install the analyzers and then keep buying reagents to run patient tests, which gives the company repeat revenue tied to how many tests are run. This puts it in China's medical device and IVD sector, and it also sells internationally.
Products & services
- Immunoassay analyzers and reagents
- Biochemistry/electrolyte analyzers
- Integrated immunoassay-biochemistry systems
- Lab automation solutions
- Molecular diagnostics solutions
- Hemolumi and rapid test solutions
新产业是做什么的？
深圳市新产业生物医学工程股份有限公司成立于1995年，总部在深圳。公司研发、生产和销售临床检验仪器和体外诊断试剂，主要客户是国内外的医院。产品包括免疫分析仪、生化/电解质分析仪、一体化系统、实验室自动化、分子诊断、血液发光及快速检测等。 公司的业务是仪器加试剂。医院装上分析仪后，要持续采购配套试剂来做检测，所以公司的收入跟检测量挂钩，会反复产生。公司属于医疗器械中的体外诊断领域，在国内和海外都有销售。
What is Shenzhen New Industries Biomedical Engineering worth?
On an owner-earnings DCF, Shenzhen New Industries Biomedical Engineering's most-likely value is about ¥69 versus a recent price near ¥52 (25% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~¥17) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Autobio Diagnostics (603658.SS) · Dian Diagnostics (300244.SZ) · Beijing Hotgen Biotech (688068.SS) · Shanghai C&D INNOSTIC Medical Technology (301584.SZ)